Aurora B SUMOylation Is Restricted to Centromeres in Early Mitosis and Requires RANBP2.

Conjugation with the small ubiquitin-like modifier (SUMO) modulates protein interactions and localisation. The kinase Aurora B, a key regulator of mitosis, was previously identified as a SUMOylation target in vitro and in assays with overexpressed components. However, where and when this modification genuinely occurs in human cells was not ascertained.

Importin-β and CRM1 control a RANBP2 spatiotemporal switch essential for mitotic kinetochore function.

Protein conjugation with small ubiquitin-related modifier (SUMO) is a post-translational modification that modulates protein interactions and localisation. RANBP2 is a large nucleoporin endowed with SUMO E3 ligase and SUMO-stabilising activity, and is implicated in some cancer types. RANBP2 is part of a larger complex, consisting of SUMO-modified RANGAP1, the GTP-hydrolysis activating factor for the GTPase RAN.

CEC enantioseparations of carboxylic acids on silica-based monoliths modified with ergot alkaloid derivative.

The enantioseparation of carboxylic acids, including amino acid dansyl-derivatives, 2-arylpropionic acids and 2-aryloxypropionic acids, was tested by CEC on a porous silica sol-gel monolithic column that was prepared by polycondensation of tetramethoxysilane in acidic conditions and post-gelation heat treatment (120 degrees C for 3 h) in the presence of urea, and successively, by anchoring to the silica (+)-1-allyl-(5R,8S,10R)-terguride as the chiral selector. The bimodal structure of the sorbent showed through pores with a median value of 1.39 mum and a mesopore size distribution ranging between 6 and 12 nm (average pore size of 9.